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Abstract 
Results obtained from completed and on-going clinical studies indicate huge therapeutic potential of stem 
cell-based therapy in the treatment of degenerative, autoimmune and genetic disorders. However, clinical 
application of stem cells raises numerous ethical and safety concerns.  
In this review, we provide an overview of the most important ethical issues in stem cell therapy, as a 
contribution to the controversial debate about their clinical usage in regenerative and transplantation 
medicine.  
We describe ethical challenges regarding human embryonic stem cell (hESC) research, emphasizing that 
ethical dilemma involving the destruction of a human embryo is a major factor that may have limited the 
development of hESC-based clinical therapies. With previous derivation of induced pluripotent stem cells 
(iPSCs) this problem has been overcome, however current perspectives regarding clinical translation of 
iPSCs still remain. Unlimited differentiation potential of iPSCs which can be used in human reproductive 
cloning, as a risk for generation of genetically engineered human embryos and human-animal chimeras, is 
major ethical issue, while undesired differentiation and malignant transformation are major safety issues. 
Although clinical application of mesenchymal stem cells (MSCs) has shown beneficial effects in the therapy 
of autoimmune and chronic inflammatory diseases, the ability to promote tumor growth and metastasis 
and overestimated therapeutic potential of MSCs still provide concerns for the field of regenerative 
medicine. 
This review offers stem cell scientists, clinicians and patient’s useful information and could be used as a 
starting point for more in-depth analysis of ethical and safety issues related to clinical application of stem 
cells. 
Key words: embryonic stem cells, induced pluripotent stem cells, mesenchymal stem cells, stem cell-based 
therapy. 
Introduction 
Stem cells have raised tremendous expectations 
among the medical doctors, researchers, patients, and 
the general public due to their capacity to differentiate 
into a broad range of cell types. Stem cell researchers 
are engaged in different endeavors, including treating 
genetic disorders and generating new stem 
cell-derived human tissues and biomaterials for use in 
pharmacy genomics and regenerative medicine. 
Results obtained from completed and on-going 
clinical studies indicate huge therapeutic potential of 
stem cell-based therapy in the treatment of 
degenerative, autoimmune and genetic disorders [1, 
2].  
However, clinical application of stem cells raises 
some ethical and safety concerns. In this review we 
provide an overview of the most important ethical 
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issues in stem cell research and therapy, as a 
contribution to the debate about their clinical use in 
regenerative and transplantation medicine. We 
describe and discuss ethical challenges regarding 
human embryonic stem cell (hESC) research, 
therapeutic potential and clinical translation of 
induced pluripotent stem cell (iPSC) and safety issues 
of mesenchymal stem cell (MSC)-based therapy.  
Our hope is that stem cell scientists and 
clinicians will use the information presented herein as 
a starting point for more in-depth analysis of ethical 
and safety issues related to clinical translation of stem 
cells since controversial regulation and application of 
stem cell therapy has been falsely celebrated not only 
in countries with lax medical regulations but also in 
many developed countries. For instance, in 2016, 351 
US businesses engaged in frequently unproven and 
direct-to-consumer marketing of different stem cell 
interventions was offered at 570 clinics [3].  
Ethical and safety concerns regarding 
hESC-based therapy 
hESCs are stem cells derived from the 
pluripotent inner cell mass of the pre-implantation 
embryos [4, 5]. hESCs express typical pluripotent 
stem cell markers such as octamer-binding 
transcription factor 3/4 (OCT3/4), stage specific 
embryonic antigens 3 and 4 (SSEA-3 and SSEA-4), 
TRA-1-60, TRA-1-81 and alkaline phosphatase, 
possess high levels of telomerase activity and show 
normal karyotype [6, 7]. hESCs have capacity to 
differentiate into cell types of all three germ layers 
[endoderm, mesoderm, and ectoderm] under in vitro 
and in vivo conditions [6, 7]. Consequently, hESCs 
hold great promise in understanding of early human 
embryology and for developing the cell replacement 
strategies for the treatment of human diseases (Figure 
1). 
Nevertheless, the ethical dilemma involving the 
destruction of a human embryo was and remains a 
major factor that has slowed down the development 
of hESC-based clinical therapies.  
The fundamental question is: Whether it is 
morally acceptable to pursue novel therapies for 
curing illnesses at the expense of destroying an early 
human embryo? This debate brings out individual 
opinions so deeply rooted in basic moral beliefs that 
developing a definitive policy acceptable to everyone 
seems unlikely. This ethical dilemma is portrayed in 
different legislation that exists throughout the world 
regulating hESCs research [8, 9]. For example, in 
many countries including United Kingdom, it is 
illegal to perform nuclear transfer (NT) for 
reproductive or therapeutic purposes, while use of 
hESCs for research is allowed. Other countries retain 
more extreme stances, as is the case of Italy where 
there is a prohibition on all hESC-based research. On 
contrary, it is legal to use supernumerary in vitro 
 
Figure 1. Schematic diagram describing characteristics of ESCs. Embryonic stem cells (ESCs) are harvested from a blastocyst. Embryonic stem (ES) cells are 
derived from the inner cell mass of the pre-implantation embryo. Fully characterized hESCs express typical pluripotent stem cell markers such as octamer-binding 
transcription factor 3/4 (OCT3/4), stage specific embryonic antigens 3 and 4 (SSEA-3 and SSEA-4), TRA-1-60, and TRA-1-81.These cells are pluripotent, meaning they 
can differentiate into cells from all three germ layers (ectoderm, mesoderm and endoderm). Main ethical issues (labeled with question marks): isolation of ESCs 
involves the destruction of a human embryo; transplantation of undifferentiated ESCs may result with a formation of teratomas, tumors that contain all three germ 
layers. 
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fertilization (IVF)-derived embryos for derivation of 
new hESCs lines and to perform NT for the generation 
of patient-specific stem cells in the United Kingdom 
[10-12]. United States banned production of any 
hESCs line that requires the destruction of an embryo 
and research using hESCs lines is limited on usage of 
lines created prior to August 9, 2001. Present 
restrictions have additionally slowed the progress of 
hESCs technology and provide a significant barrier to 
the development of cell based clinical therapies. 
Additionally, the ethical debate surrounding the 
harvest of hESCs has made research on this topic 
controversial, and as a result, the majority of studies 
were focused on animal models [13]. 
It is important to highlight that beside ethical 
concerns, safety issues regarding hESC-based therapy 
are the main problem for their clinical use. The 
pluripotency of hESCs is a double-edged sword; the 
same plasticity that permits hESCs to generate 
hundreds of different cell types also makes them 
difficult to control after in vivo transplantation [14]. 
When undifferentiated hESCs are transplanted, 
teratomas, tumors that contain all three germ layers, 
could develop [Figure 1] [15]. Studies have revealed 
that appearance of teratoma is between 33-100% in 
hESC-transplanted immunodeficient mice, depending 
on the implantation site, cell maturation, purity, and 
implantation techniques [16, 17].  
Currently, the only way to ensure that teratoma 
will not develop after hESC transplantation is to 
differentiate them in desired and mature cell type 
before injection and screen them for the presence of 
undifferentiated cells. When such procedures were 
rigorously followed, teratomas were not observed in 
over 200 animals transplanted with hESC-derived 
cardiomyocytes [18]. However, unwanted and 
uncontrolled differentiation of hESCs was still noticed 
despite following up of this procedure. Primitive 
population of nestin+ neuroepithelial cells, that 
continued to proliferate in the striatum, was noticed 
in rats with Parkinson disease, 70 days after 
transplantation of hESC-derived dopamine neurons 
[19]. This raises a cautionary flag and suggests that 
even committed progenitors can proliferate 
excessively after transplantation, a problem that may 
be solved by improving purification methods.  
However, despite these safety concerns, recently 
published data [20] suggest that under controlled 
conditions, hESC-derived cells could serve as a 
potentially safe new source in regenerative medicine.  
Clinical trial that investigates potential of 
hESC-based therapy for the treatment of diabetes 
mellitus is opened and recruitment of patients has 
begun in 2014 [21]. The goal of this study is to 
evaluate the safety and efficacy of VC-01, an implant 
containing hESCs derived pancreatic progenitor cells 
encapsulated by an immune protecting device, which 
would allow the cells to proliferate and differentiate 
into mature β-cells in vivo without the possibility of 
immune rejection [22]. 
Recently, Song and co-workers [20], reported 
that subretinal transplantation of hESC-derived 
retinal pigment epithelial cells (hESC-RPE) in four 
Asian patients: two with dry age-related macular 
degeneration and two with Stargardt macular 
dystrophy was safe and well tolerated procedure. 
Visual acuity improved 9–19 letters in three patients 
and remained stable [+1 letter] in one patient. During 
one year follow-up period, serious safety issues 
related to the transplanted cells such as: adverse 
proliferation, tumorigenicity, ectopic tissue formation, 
was not observed. Based on these encouraging results, 
during the past few years, several clinical trials are 
investigating therapeutic potential of hESC-RPE in 
patients with Stargardt macular dystrophy and 
advanced dry age related macular degeneration 
(Table 1, left panel) and promising results are 
expecting in next year. 
Advances and challenges of iPSC 
technology 
iPSC are very similar to hESCs in terms of 
karyotype, phenotype, telomerase activity and 
capacity for differentiation. However, iPSCs are 
considered morally superior to hESCs since their 
generation does not require destruction of embryos 
[23]. Takahashi and Yamanaka demonstrated the first 
direct reprogramming of mammalian somatic cells 
[24]. Up-regulation of “Yamanaka factors”: sex 
determining region Y box-containing gene 2 [SOX2], 
OCT3/4, tumor suppressor Krüppel-like factor 4 
[KLF4], and proto-oncogene c-MYC managed to 
reprogram differentiated somatic cells in the 
pluripotent state [24].  
Since then, iPSCs technology provides a historic 
opportunity to move away from embryo destruction 
and opened a new era of personalized medicine. 
Patient-specific iPSCs may be helpful in drug 
screening, generating in vitro models of human 
diseases, and novel reproductive techniques (Figure 
2). In vitro, patient-specific iPSCs can differentiate to 
specific cell types which enable testing of new drugs 
in patient-specific conditions. Since iPSC-derived cells 
are generated from somatic cells previously obtained 
from a patient, there is no risk of immune rejection 
after their transplantation [25]. The development of 
reproductive technology enables generation of 
gametes (sperm and eggs) from human iPSCs [26]. 
This technique could be helpful for treating infertility, 
however, the use of iPSC-derived gametes raises set of 
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ethical concerns related to the potential exploitation of 
created embryos, human NT, and risk of change 
natural reproduction including the possibility to 
derive gametes for same-sex reproduction, as well as 
in the asexual reproduction [26]. 
 
Table 1. Clinical trials using hESC-RPE and iPSC-derived cells  
hESC-RPE cellular therapy iPSC-derived cells in clinical trials 
Condition ClinicalTrials.gov Identifier 
number/ Phase/ Status 
Condition ClinicalTrials.gov Identifier number/ 
Source/ Status 
Age Related Macular 
Degeneration, Stargardt's Disease, 
Exudative Age-related, Macular 
Degeneration 
NCT02903576/ I/II/ study is 
currently recruiting participants 
Leukemia, Lymphoma 
 
NCT02564484/ blood/ study is 
currently recruiting participants 
Dry Age Related Macular 
Degeneration 
NCT01344993/ I/II/ study has been 
completed 
Ataxia-Telangiectasia (A-T) NCT02246491/ blood, skin/ study is 
currently recruiting participants 
Stargardt's Macular Dystrophy NCT01345006/ I/II/ study has been 
completed 
Chronic Granulomatous Disease 
 
NCT02926963/ hair, skin/ study is 
currently recruiting participants 
Dry Age-related Macular 
Degeneration 
NCT03046407/ early 1/ study is 
currently recruiting participants 
Retinoblastoma 
 
NCT02193724/ skin, blood/ study is 
currently recruiting participants 
Stargardt's Macular Dystrophy NCT01469832/ I/II/ study has been 
completed 
Autism Spectrum Disorder NCT02720939/ blood/ study is 
currently recruiting participants 
Dry Macular Degeneration, 
Geographic Atrophy 
NCT02590692/ I/II/ study is 
currently recruiting participants 
Ectodermal Dysplasia 
 
NCT02896387/ skin, cornea/ study is 
currently recruiting participants 
Dry Age-related Macular 
Degeneration 
NCT02755428/ early 1/ study is 
currently recruiting participants 
Intellectual Deficiency, Asymptomatic 
Carrier of the Mutation of the Gene 
MYT1L, Healthy Volunteers 
 
 
Macular Degeneration, 
Stargardt's Macular Dystrophy 
NCT02749734/ I/ study is currently 
recruiting participants 
NCT02980302/ skin/ study is 
currently recruiting participants 
Age-related Macular 
Degeneration 
NCT02286089/ I/II/ study is 
currently recruiting participants 
Age-related Macular 
Degeneration 
NCT03102138/ I/ study is currently 
recruiting participants 
 
 
 
Figure 2. Potential applications of human induced pluripotent stem cells (iPSCs). iPSC technology can be potentially utilized in disease modeling, drug 
discovery, gene therapy, and cell replacement therapy. Genetic mutations can be corrected by gene targeting approaches before or after reprogramming. iPSCs are 
considered morally superior then ESCs since their generation do not require destruction of embryos. Introduction of the four transcription factors-“Yamanaka 
factors“ (Oct-4, Sox-2, Klf-4, and c-Myc) leads to reprogramming of a somatic cell to an iPSC which can further differentiate into different types of cells. Two types 
of methods for the delivery of reprogramming factors into the somatic cells can be used: integrating viral vector systems and non-integrating methods. The main safety 
issue regarding iPSC-based therapy (labeled with question marks) is the risk of teratoma formation which might happen if patient receive iPSC-derived cells that 
contain undifferentiated iPSC and dilemma whether retroviral and lentiviral-free iPSC are safe for clinical application.  
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As for hESCs the main safety issue regarding 
iPSC-based therapy is the risk of teratoma formation 
which can happened if patient receive iPSC-derived 
cells that contain undifferentiated iPSC (Figure 2). 
Uncontrolled proliferation and differentiation of 
transplanted undifferentiated iPSCs may result in 
generation of tumors and/or undesired 
differentiation of iPSCs in broad range of somatic cells 
[27]. Thus, development of more effective methods for 
generation of purified populations of autologous 
iPSC-derived differentiated cells remains a challenge 
for personalized and regenerative medicine [28].  
It is important to highlight here that due to the 
genomic instability of iPSCs [29], even improved 
protocols for their differentiation, does not guarantee 
safe clinical application and underlines several 
differences compared to hESCs [30-32].  
Transformation of iPSCs into tumor cells could 
be a consequence of oncogenic properties of the 
reprogramming cocktail (use of c-MYC) [33], or 
insertional mutagenesis induced by the 
reprogramming with integrating retroviral or 
lentiviral vectors which disrupts endogenous genes 
[34]. Recently, clinical trial that investigated potential 
of autologous iPSC-RPE for the treatment of advanced 
neovascular age-related macular degeneration has 
been stopped [35]. Although transplantation of 
iPSC-RPE in the first enrolled patient was well 
tolerated after one year follow-up, study was stopped 
when it moved on to a possible second patient. Since 
iPSC, derived from second patient contained 
mutation, they did not pass a genomic validation step 
and the team led by Takahashi decided to at least 
temporarily suspend the trial. However, what 
remains unclear at this time and what should be 
explored is whether the mutation in the second 
patient’s iPSC was pre-existing in the patient’s 
fibroblasts or it occurred during the reprogramming 
process itself. 
In order to make the transition of iPSC-based 
therapy from lab to clinic, recently conducted research 
studies are focusing on identifying new molecular 
strategies that can increase cell reprogramming 
efficiency without causing genetic and epigenetic 
abnormalities in the iPSCs [36]. Several types of 
non-integrating methods have been developed [use of 
non-integrating adenoviral vectors, repeated 
transfection of plasmids, Cre–loxP– mediated 
recombination, PiggyBac-transposition] [37-41].  
Unfortunately, there is still insufficient data to 
argue that these retroviral and lentiviral-free iPSC are 
safe for clinical application (Figure 2). Accordingly, 
further in vitro and in vivo, animal, studies are 
necessary to develop optimized growth and 
differentiation protocols and reliable safety assays to 
evaluate the potential of iPSCs and iPSC-derived 
differentiated cells for clinical application in patients.  
Several clinical trials that are going to explore 
clinical potential of iPSC-derived cells are currently 
recruiting patients (Table 1, right panel) and scientific 
and public community curiously expects these results.  
Mesenchymal stem cells: key players in 
the cell-based therapy of 
immune-mediated diseases 
Mesenchymal stem cells are adult, 
fibroblast-like, multipotent cells, most frequently 
isolated from bone marrow (BM), adipose tissue (AT) 
and umbilical cord blood (UCB) [42]. The 
International Society for Cellular Therapy formulated 
minimal criteria for uniform characterization of MSCs 
such as plastic adherence, potential for differentiation 
in osteogenic, chondrogenic, and adipogenic lineage, 
cell surface expression of CD105, CD73, CD90 and the 
absence of hematopoietic markers CD45, CD34, CD14 
or CD11b, CD79α or CD19 and HLA-DR (Figure 3) 
[43].  
These cells can differentiate into a variety of cell 
types of mesodermal origin and due to their plasticity, 
some studies [44-46] claim that MSCs can differentiate 
towards cells of neuro-ectodermal (neurons, 
astrocytes, and oligodendrocytes) or endodermal 
(hepatocytes) origin [47]. In addition to their 
differentiation potential, MSCs possess broad 
spectrum of immuno-modulatory capacities [48]. 
MSCs ‘primed’ by pro-inflammatory cytokines 
(interferon gamma and tumor necrosis factor alpha) 
adopt immunosuppressive phenotype, and through 
cell-to-cell contact (engagement of the inhibitory 
molecule programmed death 1 with its ligands) or 
through the production of soluble factors 
(transforming growth factor-β (TGF-β), interleukin 
(IL)-10, hepatocyte growth factor (HGF), 
prostaglandin E2, nitric oxide, indoleamine 2,3 
dioxygenase and heme-oxygenase-1) modulate the 
adaptive and innate immune response [42, 49]. In 
addition, MSCs lack the expression of membrane 
bound molecules involved in immune rejection which 
enable their allogenic transplantation [50].  
Accordingly, the past decade has witnessed an 
outstanding scientific production focused towards the 
possible clinical applications of MSCs in the therapy 
of autoimmune and chronic inflammatory diseases 
including inflammatory bowel diseases (IBD), liver 
disorders and cardiac diseases with very encouraging 
results (Figure 3) [51-70].  
Int. J. Med. Sci. 2018, Vol. 15 
 
 
http://www.medsci.org 
41 
 
Figure 3. Differentiation ability and immune-modulatory characteristics of MSCs. MSCs are adult, fibroblast-like, multipotent cells, most frequently 
isolated from bone marrow (BM), adipose tissue (AT) and umbilical cord blood (UCB). Minimal criteria for characterization of MSCs are: cell surface expression of 
CD105, CD73, CD90 and the absence of hematopoietic markers CD45, CD34, CD14 or CD11b, CD79α or CD19 and HLA-DR. MSCs have been applied clinically 
in patients with inflammatory bowel diseases (IBD), liver disorders and cardiac diseases with very encouraging results. MSCs possess broad spectrum of 
immuno-modulatory capacities. Serious adverse events noticed in some of MSC-treated patients could be explained by the fact that MSCs either suppress or promote 
inflammation in dependence of inflammatory environment to which they are exposed to. The primary concerns for clinical application of MSCs (labeled with question 
marks) are unwanted differentiation of the transplanted MSCs and their potential to suppress anti-tumor immune response and generate new blood vessels that may 
promote tumor growth and metastasis.  
 
MSCs in IBD therapy 
Instantly, there are two routes for the 
administration of MSCs in IBDs patients: intravenous 
administration for the systemic control of intestinal 
inflammation in the therapy of luminal Chron’s 
disease (CD) and ulcerative colitis (UC), and the local 
administration as a therapeutic approach for patients 
with perianal fistulazing CD [51-58]. Administration 
of autologous or allogeneic MSCs derived from BM 
and AT achieved significant clinical efficacy in 
patients with fistulazing CD by attenuating local 
immune response and by promoting tissue repair 
[51-58].  
Results obtained in huge number of clinical trials 
[51-55] indicate that local application of autologous 
and allogeneic BM-MSCs and AT-MSCs are simple, 
safe, and beneficial therapy for the treatment of 
perianal fistulas in CD patients with no adverse 
effects. On contrary, adverse effects have been 
reported in three of nine improved clinical trials [56] 
that investigated therapeutic potential of 
intravenously injected MSCs. 
Study conducted by Duijvestein and coworkers 
[56] documented that 6 weeks after MSCs treatment, 
three patients required surgery due to disease 
worsening. Similar results were noticed in another 
clinical trial [57]. In this study, autologous MSCs, 
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derived from marrow aspirate and propagated for 2-3 
weeks with fibrinogen depleted human platelet 
lysate, were administered to IBD patients. Twelve 
patients received single MSCs intravenous infusion of 
2, 5 or 10 million cells/kg and serious adverse events 
were seen in seven patients. Aggravation of disease 
was noticed in five patients while adverse events in 
other two patients were possibly related to the 
infusion of MSCs [57].  
Moreover, serious side effects were seen in 
patients with moderate to severe UC that received 
Multistem (stem cells derived from adult BM and 
non-embryonic tissue sources) as potentially new 
therapeutic agent for the treatment of UC [58].  
Serious adverse events noticed in some of 
MSC-treated patients could be explained by the fact 
that MSCs either suppress or promote inflammation 
in dependence of inflammatory environment to which 
they are exposed to [59]. When MSCs are transplanted 
in the tissue with high levels of pro-inflammatory 
cytokines (IFN-γ, TNF-α, IL-12, IL-6, IL-17 and IL-23), 
MSCs adopt an immuno-suppressive phenotype and 
modify maturation of DCs, promote conversion of 
macrophages in anti-inflammatory M2 phenotype 
and suppress proliferation and activation of T 
lymphocytes, NK and NKT cells. In the presence of 
low levels of inflammatory cytokines, MSCs adopt a 
pro-inflammatory phenotype and produce 
inflammatory cytokines that promote neutrophil and 
T cell activation and enhance immune response and 
inflammation [59].  
MSC-based therapy of liver diseases 
Over the past few years, several clinical trials 
used MSCs to treat patients with liver diseases [60-65]. 
Obtained results demonstrated that MSCs treatment 
improved liver function in safe and well tolerated 
manner [60-65]. Amer and colleagues demonstrated 
the safety and short-term therapeutic effect of 
autologous transplantation of bone marrow 
MSCs-derived hepatocyte-like cells in patients with 
end-stage liver failure [61]. In patients with liver 
failure caused by hepatitis B virus infection, 
autologous transplantation of BM-MSCs provided 
short-term efficacy in respect to several clinical and 
biochemical parameters, but long-term outcomes 
were not markedly improved [62]. Recent studies 
reported that infusion of umbilical cord-derived 
MSCs was well tolerated in patients with 
decompensated cirrhosis, and in patients suffering 
from acute on chronic liver failure, resulting in 
significant improvement of liver function and 
increased survival rates [64, 65]. 
MSCs as a promising tool in the therapy of 
cardiac diseases 
Several studies have examined therapeutic 
potential of autologous and allogeneic MSCs in the 
treatment of acute myocardial infarction (MI) [66-70]. 
In a phase I clinical study [66], 53 patients were 
randomized to receive either allogeneic MSCs or 
placebo, 7 to 10 days after MI. An improvement of 
overall clinical status was noticed 6 months after 
intravenous infusion of MSCs. Chen and colleagues 
[67] administered autologous MSCs intra-coronary in 
patients with subacute MI and observed decreased 
perfusion defect, improved left ventricular ejection 
fraction, and left ventricular remodeling 3 months 
after therapy.  
Currently, there are several published or 
ongoing clinical trials that demonstrated beneficent 
effects of MSC-based therapy in the treatment of 
chronic ischemic cardiomyopathy. Injection of MSCs 
attenuated fibrosis, induced neo-angiogenesis, 
enhanced contractility, and improved the quality of 
life of patients with chronic ischemic cardiomyopathy 
[66-70]. Additionally, it was reported that 
intracoronary transplantation of autologous MSCs 
reduced episodes of tachycardia in patients with 
chronic ischemic cardiomyopathy and implanted 
cardioverter defibrillator [69]. Haack-Sørensen and 
co-workers performed demonstrated that 
intra-myocardial injections of autologous MSC 
significantly improve quality of life, physical 
limitation and angina stability of patients with chronic 
coronary artery disease and refractory angina [70].  
The other side of the coin: safety issues 
regarding MSCs-based therapy 
Despite these promising results, safety issues 
regarding MSCs-based therapy are still a matter of 
debate, especially in the long-term follow up. The 
primary concern is unwanted differentiation of the 
transplanted MSCs and their potential to suppress 
anti-tumor immune response and generate new blood 
vessels that may promote tumor growth and 
metastasis. 
MSCs have a potential to differentiate into 
undesired tissues, including bone and cartilage. 
Encapsulated structures were found in the infarcted 
areas of myocardium after transplantation of MSCs. 
The structures contained calcifications or ossifications 
[71]. Study conducted by Yoon et colleagues showed 
that transplantation of unfractionated BM-derived 
cells into acutely infarcted myocardium may induce 
development of intra-myocardial calcification [72].  
It was recently reported that three women 
suffering from macular degeneration, within a week 
Int. J. Med. Sci. 2018, Vol. 15 
 
http://www.medsci.org 
43 
of undergoing “adipose tissue stem cell”-based 
therapy developed complications including vision 
loss, detached retinas and bleeding and are now 
totally blind and unlikely to recover [73]. The 
treatment involved combining fat tissue removed 
from the patients’ abdomens with enzymes to obtain 
“adipose-derived” stem cells. These were mixed with 
blood plasma containing large numbers of platelets 
and injected into the women's eyes. Although, usually 
experimental eye procedures are tested on one eye 
first so that if something goes wrong the patient is still 
able to see with the other eye, in this trial both eyes 
were treated at once which, at the end, resulted with 
complete blindness in these patients.  
These results suggest that local 
microenvironment in which MSCs engraft contains 
factors that induce unwanted differentiation of 
transplanted MSCs in vivo. Therefore, new research 
studies should be focused in definition of factors and 
signaling pathways that are responsible for the fate of 
MSCs after their in vivo administration.  
In addition to unwanted differentiation, MSCs 
may bridge the gap between anti-tumor immune 
response and neo-angiogenesis in malignant diseases, 
thus promoting tumor growth and metastasis. After 
injection, MSCs migrate towards primary tumors [74] 
where due to their immuno-modulatory 
characteristics; suppress anti-tumor immune response 
resulting with an increased tumor growth [75, 76]. We 
showed that injection of human MSCs promotes 
tumor growth and metastasis in tumor bearing mice, 
which was accompanied by lower cytotoxic activity of 
NK and CD8+ T cells and increased presence of 
immuno-suppressive IL-10 producing T lymphocytes 
and CD4+Foxp3+ T regulatory cells [77]. MSCs 
promote polarization of immune response towards 
anti-inflammatory Th2 pathway creating an 
immunosuppressive environment which enables 
progression of tumor growth and metastasis [77]. 
Additionally, MSCs promote metastasis by 
enhancing generation of new blood vessels. MSCs 
have the capacity to differentiate into endothelial cells 
and to create a capillary network [78, 79]. Injected 
MSCs migrate to the metastatic sites [74] and produce 
pro-angiogenic factors: vascular endothelial growth 
factor, basic fibroblast growth factor, TGF-β, 
platelet-derived growth factor, angiopoietin-1, 
placental growth factor, IL-6, monocyte chemotactic 
protein-1, HGF, resulting with neo-vascularization 
[80].  
Conclusions 
The creation and clinical use of hESCs have long 
been the unique focus of stem cell ethics. Current 
ethical controversies regarding stem cell-based 
therapy are focused on the unlimited differentiation 
potential of iPSCs which can be used in human 
cloning, as a risk for generation of human embryos 
and human-animal chimeras.  
Since undesired differentiation and malignant 
transformation are major safety issues regarding 
transplantation of iPSCs and iPSC-derived cells, 
protocols for differentiation of iPSCs should be 
optimized in order to ensure the purity of 
iPSC-derived populations of differentiated cells 
before their clinical use. Considering the fact that 
MSCs are frequently and worldwide offered as 
universal human remedy but may promote tumor 
growth and metastasis, studies which utilize MSCs 
should be focused in continuous monitoring and 
long-term follow-up of MSC-treated animal models in 
order to determine possible pro-tumorigenic and 
other detrimental effects of MSC-based therapy.  
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